A partial clinical trial hold has been lifted from cancer drug emavusertib and Curis has selected a dose to use in Phase 2 testing. The small molecule is being developed as a potential treatment for blood cancers.
FDA Lifts Partial Hold on Curis Drug, Clearing Way for Phase 2 Leukemia Study
